<DOC>
	<DOC>NCT01465997</DOC>
	<brief_summary>Compare safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with primary safety variables including spontaneous reports of Adverse Events (AEs), withdrawal of subjects due to AEs, reporting of Serious AEs (SAEs).</brief_summary>
	<brief_title>Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Subject/legal representative is considered reliable and capable of adhering to the protocol Subject has remained seizure free and completed the Maintenance Phase of the SP0993; or subject has experienced 1 or more seizures on the first or second target dose during the SP0993 Maintenance Phase Subject is expected to benefit from participation in SP0994 in the opinion of the investigator Subject is receiving any investigational drugs or using any experimental devices in addition to LCM or CBZCR Subject experienced a seizure at the third target dose during the Evaluation Phase or Maintenance Phase of the SP0993 study Subject is taking benzodiazepines for a nonepilepsy indication Subject meets a withdrawal criterion from the previous study SP0993 Subject is experiencing an ongoing SAE from the previous study SP0993 Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (CSSRS) at Screening. Or subject has a positive response (Yes) to either Question 4 or Question 5 of the CSSRS at Screening in the "Since Last Visit" version</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lacosamide</keyword>
</DOC>